Table III.
Univariate analysis of patient and treatment variables on risk of recurrent morphea in UVA1 treatment responders
| Patient Characteristics | UVA1 Responders (n=37) | |||
|---|---|---|---|---|
| Sustained inactivity(N=20) | Recurrent activity (N=17) | Hazard Ratio (95% CI) | p-value | |
| Follow-up (month), Median (range) | 37.0 (18.3–52.8) | 10.3 (4.3–25.3) | - | |
| Age of onset (year) Mean±SD | 35.9±24.1 | 33.2±26.7 | 0.998(0.978–1.019) | 0.87 |
| Duration of disease (year) | 1.2±1.4 | 5.2±8.6 | 1.154(1.062–1.268) | 0.002 |
| Cumulative UVA1 dose J/cm2 | 3781.2±1259.4 | 3622.6±1008.4 | 1.000(0.999–1.000) | 0.56 |
| Number of treatments Mean±SD | 37.7±11.0 | 40.0±6.8 | 1.015(0.966–1.067) | 0.56 |
| Duration of treatment | 20.1±10.2 | 18.5±10.3 | 0.980(0.929–1.034) | 0.46 |
| Frequency (%) | ||||
| Sex | 0.31 | |||
| Male | 7(35%) | 3(18%) | ||
| Female | 13(65%) | 14(82%) | 1.900(0.546–6.619) | |
| Race | 0.21 | |||
| Caucasian | 18(90%) | 13(76%) | - | |
| Other | 2(10%) | 4(24%) | 2.021(0.656–6.227) | |
| Age at Enrollment | 0.75 | |||
| ≤17 | 7(35%) | 6(35%) | - | |
| >17 | 13(65%) | 11(65%) | 1.173(0.433–3.177) | |
| Subtype | 0.28 | |||
| Plaque | 4(20%) | 3(19%) | - | |
| Linear | 10(50%) | 4(25%) | 0.740(0.165–3.307) | |
| Generalized | 6(30%) | 7(44%) | 1.891(0.487–7.349) | |
| Mixed | 0(0%) | 2(13%) | 2.803(0.463–16.97) | |
| Skin Type | 0.04 | |||
| I–II | 11(55%) | 15( 88%) | - | |
| III–V | 9(45%) | 2( 12%) | 0.235(0.054–1.035) | |
*
The p-value is from two-sample t-test. All the other p-values and hazard ratios are from univariate Cox regression.